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Despite recent advances in chemotherapy for gastrointestinal cancer, a crucial factor related to poor 
prognosis is reduced tolerance to chemotherapy induced by cancer cachexia. Fish oil (FO)-derived 
eicosapentaenoic acid (EPA) modulates inflammation in patients with various malignancies; however, 
the impact of FO-enriched nutrition as a combined modality therapy on clinical outcomes remains 
controversial. We systemically analysed chronological changes in biochemical and physiological status 
using bioelectrical impedance analysis in 128 gastrointestinal cancer patients provided with or without 
FO-enriched nutrition during chemotherapy. Furthermore, we evaluated the clinical significance of 
FO-enriched nutrition and clarified appropriate patient groups that receive prognostic benefits from FO-
enriched nutrition during treatment of gastrointestinal cancer. The control group showed significant up-
regulation of serum CRP) levels and no significant difference in both skeletal muscle mass and lean body 
mass. In contrast, the FO-enriched nutrition group showed no changes in serum CRP concentration 
and significantly increased skeletal muscle mass and lean body mass over time. Furthermore, high 
CRP levels significantly correlated with reduced tolerance to chemotherapy, and FO-enriched nutrition 
improved chemotherapy tolerance and prognosis, particularly in gastrointestinal cancer patients with 
a modified Glasgow prognostic score (mGPS) of 1 or 2. We conclude that FO-enriched nutrition may 
improve the prognosis of patients with cancer cachexia and systemic inflammation (i.e., those with a 
mGPS of 1 or 2).
Gastrointestinal (GI) cancer is the most common and lethal malignancy worldwide1. Of the top ten cancers 
leading to cancer-related death, five were classified as GI cancers, including oesophageal, gastric, colorectal, hepa-
tobiliary and pancreatic cancers2. Furthermore, despite recent progress in surgical and medical treatments for 
GI cancer, these malignancies still result in 35% of all cancer deaths globally, and patients with advanced GI 
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cancer still have a poor prognosis2. Treatment for GI cancer patients is critically important in the current clinical 
situation.
Cancer cachexia occurs in up to 80% of patients with advanced cancer3, 4, especially those with gastrointestinal 
and pancreatic malignancies, and it is a major obstacle in terms of the morbidity and mortality of patients with 
advanced GI cancer5. Cancer cachexia is defined as a “multifactorial syndrome characterized by an ongoing loss 
of skeletal muscle mass that cannot be fully reversed by conventional nutritional support and leads to progressive 
functional impairment”3. Accumulating evidence has suggested that systemic inflammation related to cancer is a 
pivotal mediator for the progression of cancer cachexia, and several pro-inflammatory cytokines released by both 
tumours and the host’s immune system, including interleukins (IL) 1, 2 and 6, interferon γ and TNF-α, have been 
implicated in the pathogenesis of cachexia in GI cancer.
Accumulating evidence has revealed a strong correlation between cancer cachexia/sarcopenia and chemother-
apeutic toxicity in patients with various types of cancer6–8. Prado and colleagues analysed the association between 
the status of sarcopenia and chemotherapeutic toxicity in 55 women with advanced breast cancer resistant to 
anthracycline and/or taxane treatment and clarified that sarcopenia was a predictor for capecitabine toxicity in 
patients with metastatic breast cancer6. Similarly, two other studies demonstrated that decreased muscle mass was 
associated with an increased risk of grade 3–4 toxicity for adjuvant and palliative chemotherapy in colon cancer 
patients7, 8. Furthermore, the status of systemic inflammation could be used as a marker for predicting chemo-
therapeutic outcome and prognosis in patients with various types of cancers9, 10. Collectively, cancer cachexia, 
induced by the systemic inflammatory response to disease progression, increases the toxicity of chemotherapeutic 
treatment and exacerbates prognosis in GI cancer patients.
N-3 (omega-3) polyunsaturated fatty acids (FAs) from fish oil (FO) have plausible immune-modulating effects, 
partly caused by the formation of 3-series prostanoids and 5-series leukotrienes, with a low pro-inflammatory 
and immunosuppressive effect11, 12. Specifically, eicosapentaenoic acid (EPA) is a naturally occurring omega-3 
fatty acid found in FO and certain marine products and has been shown to have anti-genotoxic, antioxidant, and 
anti-inflammatory properties through suppressing IL-6 production, down-regulating the acute phase response 
and reducing serum concentrations of C-reactive protein (CRP) in various types of cancer13. Despite evidence 
showing the anti-tumour and anti-cachexic activity of FO treatment in an animal model of cachexia14, the poten-
tial advantages of FO-enriched supplementation in nutrition parameters, quality of life, compliance with chemo-
therapeutic treatment, and prognosis remain controversial. These advantages have not been clarified in previous 
clinical trials due to several limitations, including little chronological biochemical and physiological evidence 
showing an alteration during nutritional intervention with FO, heterogeneous patient characteristics, little rele-
vant nutritional support, and inadequate patient selection15, 16.
Previous work from our group has shown that several cytokines and serum markers reflecting the systemic 
inflammatory response, including IL-1b, IL-1ra, IL-6, IL-10, CRP, and albumin (Alb), are differentially expressed 
in serum from patients with advanced GI cancer and can be used as predictive biomarkers for postoperative 
nutritional status, morbidity and mortality in GI cancer patients17–20. To clarify the potential advantages of 
FO-enriched nutritional therapy in the treatment course of advanced GI cancer, we systemically investigated 
chronological alterations in biochemical and physiological status during chemotherapeutic treatment with or 
without FO-enriched nutrition in patients with advanced GI cancer. Furthermore, we analysed not only the 
association between FO-enriched nutritional therapy and tolerance of chemotherapeutic treatment but also the 
impact of FO-enriched nutrition on the long-term survival of these patients to identify appropriate subgroups 
eligible for FO-enriched nutrition during the treatment of advanced GI cancer.
Results
Serum CRP levels increased along with tumour progression in patients with GI cancer. First, 
we analysed the serum concentrations of CEA (carcino-embryonic antigen), carbohydrate antigen 19–9 
(CA19–9) and CRP in GI cancer patients over a treatment course with or without FO-enriched nutrition therapy 
(Supplementary Table 1, Fig. 1). Along with tumour progression, the serum concentrations of CEA and CA19-9 
significantly increased in a time-dependent manner over both treatment courses (CEA: p = 0.003, 0.06; CA19-9: 
p = 0.046, 0.009, Supplementary Table 1). Furthermore, serum CRP levels were positively correlated with serum 
CEA levels in GI cancer patients (r = 0.27, p = 0.006, Supplementary Figure 1a).
FO-enriched nutrition inhibited increases in serum CRP levels and improved skeletal muscle 
mass and lean body mass in GI cancer patients. There were no significant changes in extracellular water 
ratio (extracellular water (ECW)/ total body water (TBW)), body fat quantity, or body fat percentage between 
patients treated with or without FO-enriched nutrition during the study (Supplementary Table 1). Although 
serum CRP levels significantly increased in a time- and disease progression-dependent manner in patients 
without FO-enriched nutrition (p = 0.049, Supplementary Table 1, Fig. 1), these levels remained unchanged in 
patients receiving FO-enriched nutrition (p = 0.26). Furthermore, in contrast to significant increases in skeletal 
muscle mass and lean body mass in patients with FO-enriched nutrition (p = 0.0002, p < 0.0001, respectively, 
Supplementary Table 1, Fig. 1), neither of these parameters showed significant changes in those not receiving 
FO-enriched nutrition (p = 0.26, p = 0.19, respectively).
GI cancer patients with a modified Glasgow prognostic score of 1 or 2 showed reduced toler-
ance to chemotherapeutic treatment and poor prognosis. We next evaluated associations between 
tolerance to chemotherapy and clinicopathological factors to identify risk factors for poor tolerance to chem-
otherapeutic treatment. The results indicated that young age (P = 0.03) and high CRP levels (P = 0.011) cor-
related significantly with poor tolerance to chemotherapy (Table 1). Logistic regression analysis revealed that 
high CRP levels were an independent risk factor for poor tolerance to chemotherapy in this cohort (OR: 3.68, 
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Figure 1. Chronological alterations in biochemical and physiological status during systemic chemotherapy 
in patients with GI cancer. (Upper line) Box plots are used to represent the biochemical (serum CRP and CEA 
levels) and physiological status (skeletal muscle mass and lean body mass) of GI patients who received FO-
enriched nutrition during systemic chemotherapy. Serum CRP levels were not significantly changed in the FO-
enriched nutrition group of patients with GI cancer (p = 0.26), and there was a significant improvement in the 
skeletal muscle mass and lean body mass of this group (p = 0.0002 and p < 0.0001, respectively). (Lower line) 
Box plots are used to represent the biochemical (serum CRP and CEA levels) and physiological status (skeletal 
muscle mass and lean body mass) of GI cancer patients not receiving FO-enriched nutrition during systemic 
chemotherapy. Serum CRP levels significantly increased (p = 0.049) along with serum CEA levels (p = 0.06). 
There were no significant differences in skeletal muscle mass or lean body mass (p = 0.26 and p = 0.19, 
respectively). Statistical analysis was performed using Friedman tests. All statistical tests were two-sided. 
*P < 0.05; **P < 0.01; ***P < 0.001.
Variable n
Chemotherapeutic treatment
pSuccess (n = 79) Failure (n = 49)
Gender
Male 90 56 34 0.86 #
Female 38 23 15
Age
<71 (median)* 71 38 33 0.03* #
≧71 57 41 16
Type of GI cancer
Gastrointestinal 94 57 37 0.68 #
Hepatobiliary and 
pancreatic 34 22 12
UICC stage classification
Stage II/III 44 34 10 0.01* #
Stage IV 84 45 39
Serum CRP
<0.5 mg/dl** 99 67 32 0.011* #
≧0.5 mg/dl 29 12 17
Serum Alb
<3.5 g/dl*** 13 5 8 0.07 #
≧3.5 g/dl 115 74 41
FO-enriched nutrition
(+) 37 26 11 0.21 #
(−) 91 53 38
Table 1. Association between tolerance to chemotherapy and clinicopathological factors in GI cancer patients. 
*The median age at treatment was 71 years in the total cohort. #Chi-square test. *p < 0.05. **The cut-off value 
for serum CRP level was 0.5 mg/dl. ***The cut-off value for serum Alb level was 3.5 g/dl.
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95%CI: 1.35–10.0, p = 0.011, Table 2). Furthermore, high CRP levels were closely correlated with poor progno-
sis (p < 0.001, Supplementary Figure 1b). Using a Cox proportional hazards model, we demonstrated that high 
CRP status is an independent prognostic factor for poor overall survival (OS) in patients without FO-enriched 
nutrition (HR:2.88, 95%CI:1.26–6.54, p = 0.01, Supplementary Table 2). Collectively, our results indicate that the 
systemic inflammatory response could partly explain the poor prognosis in these patients caused by their poor 
tolerance to chemotherapy.
Next, we focused on high-risk patients with elevated serum CRP levels (modified Glasgow prognostic score 
(mGPS) of 1 or 2) to assess whether FO-enriched nutrition could affect the tolerance to chemotherapy in these 
patients. Interestingly, analysis with the chi-square test revealed that tolerance to chemotherapy tended to cor-
relate with FO-enriched nutrition in GI cancer patients with an mGPS of 1 or 2 (p = 0.05, Table 3). Based on the 
chronological changes in biochemical and physiological factors observed in all patients, FO-enriched nutrition 
may not only suppress inflammatory responses along with disease progression but also improve the nutritional 
status of cancer cachexia. These changes are expected to improve compliance with chemotherapeutic treatment, 
especially in patients with a systemic inflammatory response.
FO-enriched nutrition significantly improved prognosis in GI cancer patients with an mGPS of 
1 or 2. Finally, we evaluated the prognostic impact of FO-enriched nutrition in GI cancer patients. Survival 
curve analysis showed no significant differences between the patient groups with or without FO-enriched nutri-
tion among the total cohort (p = 0.84, Fig. 2a). However, the patients with an mGPS of 1 or 2 had a significantly 
better prognosis when they received FO-enriched nutrition (p = 0.0096, Fig. 2b). In addition, analysis using 
a Cox proportional hazards model demonstrated that FO-enriched nutrition is an independent predictor for 
improvement of prognosis in patients with an mGPS of 1 or 2 (HR:0.24, 95%CI: 0.06–0.98, p = 0.045, Table 4). 
Collectively, our data clearly show that FO-enriched nutrition could improve chemotherapeutic treatment com-
pliance and prognosis in patients with an mGPS of 1 or 2.
Discussion
Over the past decade, although growing evidence has supported the anti-tumour and anti-inflammatory effect of 
FO treatment, the clinical feasibility of FO-enriched nutrition for GI cancer patients remains controversial15, 16. 
Furthermore, the clinical feasibility of FO-enriched nutrition therapy and its impact on clinical outcomes in 
these patients when given during systemic chemotherapy has never been evaluated. In this study, we system-
atically investigated the clinical benefit of providing FO-enriched nutrition during systemic chemotherapy in a 
large cohort of patients with GI cancer. We made several important discoveries during this investigation. First, 
along with tumour recurrence and progression, the systemic inflammatory response (as reflected by serum CRP 
concentration) was increasingly activated during chemotherapy in patients not given FO-enriched nutrition. 
Variables
Univariate Multivariate
OR 95%CI p value OR 95%CI p value
Gender (male) 0.93 0.43–2.03 0.86 0.87 0.37–2.04 0.74
Age (≧71 years old)# 0.45 0.21–0.94 0.03 0.45 0.2–1.01 0.05
Type of gastrointestinal cancer 0.81 0.56–1.17 0.26 0.69 0.45–1.05 0.09
UICC TNM stage classification 1.7 0.94–3.09 0.08 1.79 0.95–3.37 0.07
High serum CRP levels (≧0.5 mg/dl) 2.97 1.27–6.94 0.012* 3.68 1.35–10.0 0.011*
High serum Alb levels (≧3.5 g/dl) 0.35 0.11–1.13 0.08 0.38 0.1–1.51 0.17
With/without FO-enriched nutrition 0.59 0.26–1.34 0.21 0.41 0.15–1.08 0.07
Table 2. Multivariate analysis to identify predictors of tolerance to chemotherapeutic treatment in GI cancer 
patients. #The median age at treatment was 71 years in this cohort. OR: Odds ratio. *p < 0.05.
Variable n
Chemotherapeutic treatment
pSuccess (n = 12) Failure (n = 17)
Gender
Male 22 8 14 0.77 #
Female 7 4 3
Age
<72 (median)* 15 4 11 0.1 #
≧72 14 8 6
Type of GI cancer
Gastrointestinal 19 8 11 0.91 #
Hepatobiliary and pancreatic 10 4 6
UICC stage classification
Stage II/III 8 5 3 0.16 #
Stage IV 21 7 14
FO-enriched nutrition
(+) 12 8 4 0.05 #
(−) 17 5 12
Table 3. Association between tolerance to chemotherapy and clinicopathological factors in patients with GI 
cancer and an mGPS of 1 or 2. *The median age at treatment was 72 years. #Chi-square test.
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In contrast, the systemic inflammatory response remained stable despite disease progression in patients who 
received FO-enriched nutrition. Skeletal muscle mass and lean body mass remained at steady levels in patients 
without FO-enriched nutrition, whereas both parameters increased significantly even under systemic chemother-
apy in patients who received FO-enriched nutrition. Second, we showed that patients with systemic inflammation 
exhibit significantly reduced tolerance to chemotherapy and that FO-enriched nutrition improved adherence 
to chemotherapy in GI cancer patients with an mGPS of 1 or 2. Finally, our data clearly demonstrated that 
FO-enriched nutrition significantly improved prognosis and was as an independent factor of improved prognosis 
for OS in GI cancer patients with systemic inflammation (mGPS 1 or 2).
Cachexia, which can be accompanied by skeletal muscle wasting and malnutrition, is a frequent problem in 
patients with malignant disease. Accumulating evidence has revealed an intimate association between cachexia 
and deterioration of functional status, reduced quality of life, low tolerance to chemotherapy, and poor prog-
nosis in patients with GI cancer21. Furthermore, patients with advanced cancer generally develop skeletal mus-
cle wasting, with a loss of 1.1 kg of skeletal muscle mass over the duration of chemotherapy (≥2.5 months)22. 
Based on this evidence and with recent advances in aggressive chemotherapy, oncologists are re-focusing their 
attention onto the management of nutritional status during systemic chemotherapy as a clinically relevant fac-
tor for supportive care. Nutritional intervention has become a widely accepted strategy for patients with cancer 
cachexia23. Furthermore, several studies have successfully demonstrated a positive effect of FO supplementation, 
especially with EPA, on skeletal muscle mass and lean body mass in cancer patients24. Fearon and colleagues 
conducted a double-blind, randomized, placebo-controlled study examining a large cohort of GI cancer and 
lung cancer patients and demonstrated a significant increase in body weight in patients receiving daily supple-
mentation with 2 g EPA15. Other groups have also recently evaluated the effect of FO-derived EPA supplementa-
tion in non-small cell lung cancer (NSCLC) patients during chemotherapy25. In the present study, a significant 
reduction in whole-body skeletal muscle was observed during chemotherapy in patients without FO-enriched 
nutrition, whereas this chemotherapy related decline in skeletal muscle mass was prevented in patients receiv-
ing FO-enriched nutrition. Although a growing number of studies have demonstrated the potential benefits 
Figure 2. Prognostic impact of FO-enriched nutritional intervention in GI cancer patients. (a) Kaplan–Meier 
survival curves showing the OS of GI cancer patients in association with the nutritional intervention in the 
total cohort (n = 128). The OS rate of the GI cancer patients receiving the nutritional intervention (n = 37) 
did not significantly change compared with those not receiving FO-enriched nutrition (n = 91) (P = 0.84; log-
rank test). (b) OS analysis of GI cancer patients with an mGPS of 1 or 2 based on treatment with FO-enriched 
nutrition. The patients with an mGPS of 1 or 2 who received FO-enriched nutrition had a better prognosis than 
the patients with an mGPS of 1 or 2 who did not receive FO-enriched nutrition (p = 0.0096; log-rank test). All 
statistical tests were two-sided.
Variables Univariate Multivariate
Gender (male)
HR 95%CI p value HR 95%CI p value
1.17 0.32–4.24 0.81 0.92 0.19–4.38 0.92
Age (≧72-year-old)# 0.57 0.2–1.64 0.29 0.76 0.19–2.95 0.69
Type of gastrointestinal cancer 2.02 0.91–4.49 0.08 2.39 0.86–6.62 0.09
UICC TNM stage classification 0.77 0.34–1.75 0.54 1.53 0.59–4.00 0.38
With/Without FO-enriched nutrition 0.23 0.07–0.75 0.015* 0.24 0.06–0.98 0.045*
Table 4. Multivariate analysis to identify predictors of overall survival in GI cancer patients with an mGPS of 1 
or 2. #The median age at treatment was 72 years in this cohort. HR: Hazard ratio. *p < 0.05.
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of FO and EPA supplementation for ameliorating cachexia in patients with various types of cancer, whether 
FO-enriched nutrition has any benefits in the clinical setting or a prognostic impact on GI cancer patients 
remains unclear. One key finding from our study is that FO-enriched nutrition inhibited an exaggerated sys-
temic inflammatory response and ameliorated sarcopenia. These previous reports combined with our present 
data clearly suggest that FO-enriched nutrition plays a pivotal role in controlling the inflammatory response and 
maintaining nutritional status during chemotherapy in GI cancer patients.
Another key finding of the current study is that a high serum CRP level (mGPS 1 or 2) is an independ-
ent predictive factor for treatment interruptions or cessation of systemic chemotherapy in GI cancer patients. 
Moreover, FO-enriched nutrition may improve tolerance to chemotherapy and thus improve prognosis, especially 
in patients with systemic inflammation (mGPS 1 or 2). The clinical status of the systemic inflammatory response 
(based on CRP level) has been identified as an independent prognostic factor in various types of cancer, and 
several lines of evidence have suggested that systemic inflammation has an important role in aggravating sarco-
penia. Sarcopenia is also closely correlated to poor performance status (PS)26, increased risk of chemotherapeutic 
toxicity6, and reduced survival in cancer patients27.
Interestingly, recent evidence from a randomized clinical trial comparing ruxolitinib and a placebo revealed 
an association between tolerance to chemotherapy and systemic inflammation status in patients with metastatic 
pancreatic cancer28. In that study, one-hundred and twenty-seven pancreatic cancer patients with distant metas-
tasis were randomly assigned for treatment with either the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib or a 
placebo in conjunction with a capecitabine treatment course. Despite a non-significant difference in the prognosis 
of the treatment and control groups in terms of OS, benefits of ruxolitinib were seen in subgroups of patients 
with elevated CRP levels. Based on this evidence and the anti-inflammatory effect of FO-enriched nutrition, our 
findings are highly consistent with these data. Taken together, the results from the present study clearly suggest 
that the systemic inflammatory response might be directly involved in driving sarcopenia and poor tolerance to 
chemotherapy in GI cancer patients and that serum CRP levels could be used as a biomarker for selecting patients 
undergoing systemic chemotherapy who need FO-enriched nutrition.
Although our findings successfully demonstrated the clinical feasibility of providing an FO-enriched nutri-
tional intervention to GI cancer patients receiving systemic chemotherapy, this study is still considered “proof 
of principle” and had several limitations. First, the patients receiving the intervention took FO-enriched oral 
nutritional supplements, whereas the patients not undergoing the intervention did not receive any additional 
nutritional treatment or placebo. Therefore, careful interpretation of our results is needed, and we acknowledge 
that the clinical feasibility and prognostic impact of FO-enriched nutrition might be affected not only by EPA 
nutrition but also by docosahexaenoic acid (DHA) or other nutritional components. Additionally, we performed 
a power calculation that estimated a minimum statistical power for our study because of our small sample size. 
Furthermore, we examined a single-institution, retrospective cohort. Therefore, an additional large-cohort, 
double-blind, multi-institutional, prospective study with multiple arms, including nutritional supplementation 
with EPA, nutritional supplementation with DHA, nutritional supplementation without FO, and a placebo, is 
needed to better clarify the clinical effect of FO and to provide supporting evidence for these novel findings. 
Finally, we used a bioimpedance technique to assess body composition in the current study. This method has the 
potential to underestimate fat mass and overestimate fat-free mass, especially in obese people and in certain eth-
nic groups. From this point of view, additional studies using other imaging analysis techniques to more precisely 
evaluate body composition may help uncover the pivotal role of FO-enriched nutrition in GI cancer patients.
In summary, our systematic and comprehensive assessment provided novel evidence for the clinical feasibility 
of providing FO-enriched nutrition during systemic chemotherapy for patients with GI cancer. Nutritional inter-
ventions with FO supplementation could be one component in a multimodal therapeutic approach for GI cancer, 
especially in patients with high serum CRP levels (mGPS 1 or 2). The present study also highlighted the need 
for better ways to control patient symptoms from chemotherapy to prevent discontinuation of fish oil-enriched 
nutrition, and thus ensure best prognosis.
Methods
Patients and Methods. A total of 179 patients who received therapeutic chemotherapy for advanced 
or recurrent GI cancer (consisting of oesophageal, gastric, colorectal, biliary and pancreatic cancers) at the 
Department of Medical Oncology in Iga City General Hospital (Iga, Mie, Japan) between April 2011 and April 
2014 were enrolled in this retrospective cohort study. All patients had a clinical diagnosis of gastrointestinal 
cancer (radiological/histological/cytological confirmation), were between the ages of 18 and 80 years, and experi-
enced a 5% or greater loss of pre-illness body weight. The patients had a life expectancy of three months or longer 
and a Karnofsky performance status of 70 or higher3. In the FO-enriched nutrition group, fifty-one patients quit 
the FO-enriched nutritional treatment during the study due to poor compliance and were therefore excluded. 
Fifty-one patients discontinued nutritional treatment, citing several reasons and circumstances related to drop-
ping out of treatment. Discontinuation of nutritional treatment was defined when the patient stopped internal use 
of fish oil-enriched oral nutritional supplements for successive period sustained more than 7 days even just for 
once during the course of the study. The reasons for discontinuation were progressive early satiety sensation and/
or dysgeusia developed as the side effects of systemic chemotherapy (58.8%), treatment-dissatisfaction (29.4%) 
and cost (11.8%). As a result, 128 patients were assessed during adjuvant or palliative chemotherapy (44 patients 
for adjuvant chemotherapy and 84 patients for palliative chemotherapy). The patients underwent measurements 
of body composition, including total body weight, skeletal muscle mass, body fat quantity, body fat percentage, 
lean body mass and extracellular/total body water, every time they visited the clinic every three months. The 
criterion for tolerance of systemic chemotherapy was the completion of cancer treatment as planned (defined as 
completing the initially planned chemotherapy course without later modifications or early discontinuation), as 
previously described29. The Tumour Node Metastasis (TNM) staging system from the American Joint Committee 
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on Cancer was used for pathological tumour staging of gastrointestinal cancer30. During each hospital visit every 
three months, all patients underwent a chest X-ray and abdominal computed tomography. Patients who were 
treated with radiotherapy or chemotherapy before surgery were excluded from the study. The diagnosis of gas-
trointestinal cancer was confirmed for all enrolled patients based on clinicopathological findings. Patients were 
randomly assigned to a treatment course with or without FO-enriched nutrition by the healthcare staff. Patients 
in the FO-enriched nutrition group received one or two packs of FO-enriched oral nutritional supplements per 
day according to their tolerance for FO-enriched nutrition (Prosure®, Abbott Nutrition, Tokyo, Japan) and took 
the product for six months. Each pack contained 16 g of protein, 1.1 g of EPA, 0.5 g of DHA, and a total of 355 kcal. 
In contrast, patients who did not receive FO-enriched nutrition were not given any additional nutritional treat-
ment or placebo. Patient characteristics are summarized in Table 5. All methods in this study were performed 
in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all 
patients, and the study was approved by the Institutional Review Board of Iga City General Hospital.
Measurements. Routine laboratory measurements, including serum CRP and albumin, were carried out on the 
same day. No patients showed clinical evidence of infection at any measurement point. Serum CEA and CA19-9 were 
also routinely measured at the same time using an enzyme immunoassay on a Tosoh AIA 21 (Diamond Diagnostics, 
Holliston, MA, USA). Analysis of body composition, including total body weight, height, body mass index (BMI), 
lean body mass, fat mass, skeletal muscle mass, body fat quantity, body fat percentage, and extracellular/total body 
water, was conducted using bioelectrical impedance (InBody®, Cerritos, CA, USA) every three months.
The mGPS was determined as previously described31, 32. Briefly, patients with elevated CRP (>0.5 mg/dl) were 
given a score of 1 or 2 depending on the absence or presence of hypoalbuminemia (<3.5 g/dl). Patients with a 
normal CRP and any albumin level were given a score of 0.
Statistical methods. Statistical analysis was performed using Medcalc version 16.4 (Broekstraat 52, 9030; 
Mariakerke, Belgium). The results are expressed as the mean ± standard deviation (SD). Differences between 
groups were estimated using the chi-square test, Student’s t-test, and the Friedman test when appropriate. F-tests 
were conducted to assess the equality of variance for comparable groups. For time-to-event analyses, survival 
estimates were calculated using Kaplan-Meier analysis, and groups were compared with the log-rank test. OS was 
measured from the date the patient underwent surgery to the date of death resulting from any cause or the last 
known follow-up for patients who were still alive. Cox’s proportional hazards model was used to estimate hazard 
ratios (HRs) for death. Assumption of proportionality was confirmed for the Cox proportional hazards analyses 
by generating Kaplan-Meier survival curves (e.g., groups with vs. without FO-enriched nutrition) and by ensur-
ing that the two curves did not intersect with one another. Multivariate logistic regression models were used to 
predict factors influencing tolerance to systemic chemotherapy. Forced-entry regression was used to include these 
variables in all multivariable equations in order to analyse whether each of the predictors affected the outcome 
after adjusting for known confounders. Tests for an interaction were performed using the likelihood ratio test of 
cross-product terms. All P values were 2-sided, and those less than 0.05 were considered statistically significant.
Sample size justification. With regard to the sample size used for the present study to assess the perfor-
mance of prognostic markers for survival, power calculations were performed based on a detection difference of 
0.05 between treatment and non-treatment groups. Based on the patient number and distribution in this study 
(n = 37 for the treatment group and n = 91 for the control group), we estimated a 99.9% and 100% power to 
substantiate a HR of 3 and 4, respectively, for predicting prognostic outcomes at a significance level of 0.05. 
Furthermore, focusing only on the patients with high CRP levels (n = 13 for the treatment group and n = 16 for 
the control group), enough estimated power (75.5% and 86.2%) to substantiate HRs of 3 and 4 could be achieved 
for predicting prognostic outcomes.
Data availability. The datasets analysed during the current study are available from the corresponding 
author upon reasonable request.
With FO-enriched 
nutrition (n = 37)
Without FO-enriched 
nutrition (n = 91) p value
Gender
Male (n = 90) 26 64 0.99#
Female (n = 38) 11 27
Age (mean ± SD) 72.3 ± 8.4 68.9 ± 10.3 0.08*
Type of GI cancer
Gastrointestinal 25 69 0.34#
Hepatobiliary and pancreatic 12 22
UICC Stage classification
II/III 12 32 0.77#
IV 25 59
Table 5. Patient characteristics and comparison between clinicopathological factors and treatment course in 
patients with GI cancer. *Student’s t-test, #Chi-square test.
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